Recent Company News

• 08:47 AM ET Sep 24, 2025
  

  Akari Therapeutics says preclinical data demonstrates the potential of its novel ADC spliceosome modulating payload, PH1 ($0.76, 0.00)

• 08:23 AM ET Sep 18, 2025
  

  StreetAccount Summary - US Pre-market trading

• 09:20 AM ET Sep 17, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:46 AM ET Sep 17, 2025
  

  Akari Therapeutics announces filing for new patent for novel ADC platform ($0.76, 0.00)

• 05:04 PM ET Aug 29, 2025
  

  Akari Therapeutics enters share purchase agreement with White Lion Capital - 8-K ($0.76, 0.00)

• 10:01 AM ET Aug 15, 2025
  

  JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

• 05:10 PM ET Aug 13, 2025
  

  Akari Therapeutics reports Q2 EPS $0.00 vs year-ago $0.00 - 10-Q ($0.98, 0.00)

• 05:22 PM ET Jul 29, 2025
  

  Akari Therapeutics files $75M mixed shelf - S-3 ($1.08, 0.00)

• 08:54 AM ET Jul 18, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:27 AM ET Jul 18, 2025
  

  Akari Therapeutics initiated buy at Maxim Group ($1.13, 0.00)